Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status Prescription; Discontinued
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 70518-0916; 0904-6939; 51927-0072; 49452-3650; 0003-6337; 60429-265; 55154-7143; 0003-0830; 10135-702; 71770-120; 49884-724; 55512-0003; 68084-284; 51552-0851; 17337-0022; 0003-6336; 35369-0006; 0555-0882; 0003-6335; 42291-321; 51927-2655; 71052-323; 69315-164; 17337-0023; 71770-105
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.000799%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.0010.002131%Not Available
Actinic keratosis23.01.06.0010.003197%Not Available
Acute hepatic failure09.01.03.0010.000139%Not Available
Acute leukaemia01.10.02.001; 16.01.02.0010.000347%Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.001737%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000208%Not Available
Acute respiratory distress syndrome22.01.03.0010.000208%
Acute respiratory failure14.01.04.004; 22.02.06.0010.000278%Not Available
Alanine aminotransferase increased13.03.01.0030.001865%
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.0030.000208%Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaemia01.03.02.0010.017583%
Anaemia macrocytic01.03.02.002; 14.12.01.0020.000533%Not Available
Anaemia megaloblastic01.03.02.003; 14.12.01.003--Not Available
Angina unstable02.02.02.004; 24.04.04.0040.000533%Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Apathy19.04.04.0020.000533%Not Available
Aphasia17.02.03.001; 19.21.01.0010.000208%
Aplastic anaemia01.03.03.0020.000208%Not Available
Arrhythmia02.03.02.0010.000208%Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.0030.001865%Not Available
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.000139%
Aspartate aminotransferase increased13.03.01.0060.002131%
Asthenia08.01.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene